VECTURA GROUP 
By
Vectura Group plc
Investor Day
Chippenham, UK - 24 January 2014: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") confirms that it will host an investor day for research analysts and institutional investors on Wednesday 26th March 2014.
The meeting will start at 13.30 GMT in London at the offices of FTI Consulting (9th Floor, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD). Chris Blackwell, Chief Executive of Vectura, will host the meeting, which will include presentations from Vectura management and KOLs in areas linked to the work in which Vectura is involved.
The aim of the event is to provide the audience with more detail on Vectura's business strategy and to provide a better understanding of the significant growth opportunities for the Company, in addition to an update on recent pipeline developments. No material new information on current trading or future financial performance will be disclosed in these presentations.
In accordance with its normal reporting timetable, Vectura will be issuing its full year results on 21 May 2014.
A live webcast of Vectura's investor day, with the presentation slides, will be available on:
http://www.vectura.com/investors/reports-presentations/2014.aspx.
The webcast will be available following the event.
-Ends-
Enquiries
Vectura Group plc | +44 (0)1249 667700 |
Chris Blackwell, Chief Executive | |
Karl Keegan, Corporate Development Director | |
FTI Consulting | +44 (0)20 7831 3113 |
John Dineen / Ben Atwell |
About Vectura
Vectura Group plc and its subsidiaries ("Vectura" or the "Group") is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airway-related diseases. This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $30 billion worldwide.
Vectura has seven products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline (GSK), UCB and Tianjin King York Group Company Limited (KingYork).
Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website atwww.vectura.com.
Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is provided by RNS
|
distributed by
|
